Abbvie Sustainability Profile
AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
DitchCarbon Score
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbvie's score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbvie's reported carbon emissions
In 2024, AbbVie reported total Scope 1 emissions of approximately 300,072,000 kg CO2e and Scope 2 emissions of about 122,287,000 kg CO2e. This represents a decrease from 2023, where Scope 1 emissions were about 328,259,000 kg CO2e and Scope 2 emissions were approximately 131,232,000 kg CO2e. AbbVie has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. This commitment is part of their broader strategy to enhance sustainability and includes increasing the sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. Additionally, AbbVie aims for 79.1% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2027. The company has also committed to achieving net zero emissions by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect AbbVie's commitment to addressing climate change and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
How Carbon Intensive is Abbvie's Industry?
How Carbon Intensive is Abbvie's Location?
Abbvie's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abbvie has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Abbvie's sustainability data and climate commitments